"Rifampin" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A semisynthetic antibiotic produced from Streptomyces mediterranei. It has a broad antibacterial spectrum, including activity against several forms of Mycobacterium. In susceptible organisms it inhibits DNA-dependent RNA polymerase activity by forming a stable complex with the enzyme. It thus suppresses the initiation of RNA synthesis. Rifampin is bactericidal, and acts on both intracellular and extracellular organisms. (From Gilman et al., Goodman and Gilman's The Pharmacological Basis of Therapeutics, 9th ed, p1160)
MeSH Number(s)
D03.549.811.700
D04.345.295.750.700
Below are MeSH descriptors whose meaning is more general than "Rifampin".
Below are MeSH descriptors whose meaning is more specific than "Rifampin".
This graph shows the total number of publications written about "Rifampin" by people in Harvard Catalyst Profiles by year, and whether "Rifampin" was a major or minor topic of these publication.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1994 | 2 | 1 | 3 |
| 1996 | 1 | 1 | 2 |
| 1997 | 1 | 1 | 2 |
| 1998 | 4 | 1 | 5 |
| 2001 | 3 | 1 | 4 |
| 2002 | 1 | 1 | 2 |
| 2003 | 0 | 5 | 5 |
| 2004 | 3 | 4 | 7 |
| 2005 | 1 | 6 | 7 |
| 2006 | 0 | 6 | 6 |
| 2007 | 1 | 1 | 2 |
| 2008 | 1 | 2 | 3 |
| 2009 | 0 | 3 | 3 |
| 2010 | 0 | 2 | 2 |
| 2011 | 4 | 7 | 11 |
| 2012 | 4 | 5 | 9 |
| 2013 | 1 | 4 | 5 |
| 2014 | 6 | 4 | 10 |
| 2015 | 1 | 4 | 5 |
| 2016 | 5 | 6 | 11 |
| 2017 | 7 | 6 | 13 |
| 2018 | 5 | 9 | 14 |
| 2019 | 9 | 10 | 19 |
| 2020 | 3 | 12 | 15 |
| 2021 | 6 | 14 | 20 |
| 2022 | 2 | 11 | 13 |
| 2023 | 0 | 9 | 9 |
| 2024 | 0 | 2 | 2 |
Below are the most recent publications written about "Rifampin" by people in Profiles.
-
Estimation of country-specific tuberculosis resistance antibiograms using pathogen genomics and machine learning. BMJ Glob Health. 2024 Mar 28; 9(3).
-
Multidrug-resistant tuberculosis. Nat Rev Dis Primers. 2024 Mar 24; 10(1):22.
-
Pharmacokinetics and safety of first-line tuberculosis drugs rifampin, isoniazid, ethambutol, and pyrazinamide during pregnancy and postpartum: results from IMPAACT P1026s. Antimicrob Agents Chemother. 2023 11 15; 67(11):e0073723.
-
Global burden of disease due to rifampicin-resistant tuberculosis: a mathematical modeling analysis. Nat Commun. 2023 10 04; 14(1):6182.
-
Adaptation and validation of a TB stigma scale for adolescents in Lima, Peru. Int J Tuberc Lung Dis. 2023 10 01; 27(10):754-760.
-
1-Year Incidence of Tuberculosis Infection and Disease Among Household Contacts of Rifampin- and Multidrug-Resistant Tuberculosis. Clin Infect Dis. 2023 09 18; 77(6):892-900.
-
Mycobacterium tuberculosis carrying the rifampicin drug-resistance-conferring rpoB mutation H445Y is associated with suppressed immunity through type I interferons. mBio. 2023 Oct 31; 14(5):e0094623.
-
Pharmacogenetic interactions of efavirenz or rifampin and isoniazid with levonorgestrel emergency contraception during treatment of HIV or tuberculosis. Pharmacogenet Genomics. 2023 08 01; 33(6):126-135.
-
Outcomes of WHO-conforming, longer, all-oral multidrug-resistant TB regimens and analysis implications. Int J Tuberc Lung Dis. 2023 06 01; 27(6):451-457.
-
Protocol for a systematic review of long-term physical sequelae and financial burden of multidrug-resistant and extensively drug-resistant tuberculosis. PLoS One. 2023; 18(5):e0285404.